ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 335

Cross-Cultural Validity of Functional Status Assessment Measures for Rheumatoid Arthritis

Stephanie Kulhawy-Wibe1, JoAnn Zell2,3, Kaleb Michaud4, Jinoos Yazdany5, Linda S. Ehrlich-Jones6,7, Carter Thorne8, Donna Everix9 and Claire Barber10, 1University of Calgary, Calgary, AB, Canada, 2Denver Health, Denver, CO, 3University of Colorado, Denver, CO, 4Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5University of California, San Francisco, San Francisco, CA, 6Shirley Ryan AbilityLab, Chicago, IL, 7Northwestern University Feinberg School of Medicine, Chicago, IL, 8University of Toronto, Newmarket, ON, Canada, 9OnMyCare Home Health, Fremont, CA, 10Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: functional status and rheumatoid arthritis (RA), Health Assessment Questionnaire, PROMIS

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Measures and Measurement of Healthcare Quality Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Functional Status Assessment Measures (FSAMs) are important outcome measures in Rheumatoid Arthritis (RA) as poor function is a predictor for mortality and associated with lower quality of life and work disability. FSAMs inform assessment and treatment as part of guideline-based care. The Health Assessment Questionnaire (HAQ) and its derivatives are standardized and validated FSAMs commonly used in RA. More recently the Patient-Reported Outcomes Measurement Information System (PROMIS) has been developed and includes FSAMs. The HAQ and PROMIS measures were developed and validated in English, but have been translated and culturally adapted for use in other countries. Our objective was to conduct a systematic review of the cross-cultural validity of FSAMs for RA including HAQ and HAQ-derived measures as well as PROMIS measures.

Methods: Four electronic medical databases (MEDLINE, EMBASE, Cochrane Library and CINHAL) were searched in accordance with a published strategy from the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) group. The references of each included article were then manually searched for additional relevant studies. Included studies were evaluated using the COSMIN tool for cross-cultural validity and were scored as excellent, good, fair or poor.

Results: Of 58 papers identified, by our search strategy and 3 identified by manual search, 39 were included: 29 described the translation, cultural adaptation or cross-cultural validity of the HAQ-DI, 8 other HAQ derivatives, and 2 the PROMIS measures, representing 22 languages (Table). Of the 39 papers reviewed, 35 described translation, 31 described cultural adaptation, and only 3, examined cross-cultural validity of translated versions. There was generally poor adherence to proposed guidelines for cross-cultural adaptations of measures. No studies were rated as excellent by the COSMIN tool, only 4 studies were rated as good, 10 were rated fair, and 25 were rated as poor. Two studies that looked at cross-cultural validity noted differential item functioning (DIF) between Dutch and US populations for the HAQ-II and PROMIS measures and a third study found DIF between Turkish and UK populations on the HAQ.

Conclusion: FSAMs have been widely used both in their validated English form and in many translated forms. This review highlights a paucity of data on the cross-cultural validity of FSAMs and the mostly poor or fair quality methods by which they were translated and adapted. This needs to be considered when using these measures for multinational clinical trials and for day-to-day use in practice.


Disclosure: S. Kulhawy-Wibe, None; J. Zell, None; K. Michaud, None; J. Yazdany, None; L. S. Ehrlich-Jones, None; C. Thorne, Amgen Inc., 2, 5, 9,Pfizer, Inc., 2, 5, 9,UCB, Inc., 9,AbbVie Inc., 2, 5, 9,Medexus/Medac, 2, 5, 8,Eli Lilly and Co., 9,Merck & Co., 9,Hospira, 5, 9,Janssen, 9,Sanofi Genzyme, 5, 9,Celgene Corporation, 9,CaREBiodam, 9,Centocor, 5,Novartis, 9; D. Everix, None; C. Barber, None.

To cite this abstract in AMA style:

Kulhawy-Wibe S, Zell J, Michaud K, Yazdany J, Ehrlich-Jones LS, Thorne C, Everix D, Barber C. Cross-Cultural Validity of Functional Status Assessment Measures for Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cross-cultural-validity-of-functional-status-assessment-measures-for-rheumatoid-arthritis/. Accessed January 29, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cross-cultural-validity-of-functional-status-assessment-measures-for-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences